We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Byondis Initiates Phase I Study of Antibody-Drug Conjugate Cancer Therapy
Product News

Byondis Initiates Phase I Study of Antibody-Drug Conjugate Cancer Therapy

Byondis Initiates Phase I Study of Antibody-Drug Conjugate Cancer Therapy
Product News

Byondis Initiates Phase I Study of Antibody-Drug Conjugate Cancer Therapy


Want a FREE PDF version of This Product News?

Complete the form below and we will email you a PDF version of "Byondis Initiates Phase I Study of Antibody-Drug Conjugate Cancer Therapy"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Byondis B.V. has announced that the first cancer patients have started treatment with its investigational antibody-drug conjugate (ADC) SYD1875.

The First-in-Human Dose-Escalation and Expansion Study with the Antibody-Drug Conjugate SYD1875 will evaluate the safety, pharmacokinetics and preliminary efficacy of SYD1875 in patients with 5T4-expressing, locally advanced or metastatic solid tumors. While 5T4 plays an important role in the development of cancer, there are currently no drugs that target this specific tumor antigen. Patients are currently being enrolled in leading European oncology centers: Institut Jules Bordet in Brussels, Belgium; Institut Bergonié in Bordeaux, France; and Centre Oscar Lambret in Lille, France.

“It is exciting and gratifying to know that SYD1875 has progressed to the clinical study phase, giving us the opportunity to explore the potential of another promising antibody-drug conjugate,” said Byondis CEO Marco Timmers, PhD. “Our ADC technologies aim to outsmart relentless cancers and improve patient outcomes by offering better tumor-killing properties with lower side effects.”

SYD1875 is the second Byondis ADC to progress to clinical studies. The company’s anti-HER2 ADC [vic-]trastuzumab duocarmazine (SYD985) is its most advanced ADC, targeting a range of HER2-expressing cancers such as metastatic breast cancer and endometrial (uterine) cancer.

Advertisement